Loading...
CME logo

CME Group Inc.NasdaqGS:CME Aktienübersicht

Marktkapitalisierung US$104.5b
Aktienkurs
US$281.25
US$308.2
8.7% unterbewertet intrinsischer Abschlag
1Y1.7%
7D-0.3%
Wert des Portfolios
Siehe

CME Group Inc.

NasdaqGS:CME Lagerbericht

Marktkapitalisierung: US$104.5b

CME Group (CME) Aktienübersicht

Die CME Group Inc. betreibt zusammen mit ihren Tochtergesellschaften weltweit Kontraktmärkte für den Handel mit Futures und Optionen auf Futures-Kontrakte. Mehr Details

CME grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum0/6
Vergangene Leistung4/6
Finanzielle Gesundheit6/6
Dividenden3/6

CME Community Fair Values

Create Narrative

See what 81 others think this stock is worth. Follow their fair value or set your own to get alerts.

CME Group Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für CME Group
Historische Aktienkurse
Aktueller AktienkursUS$286.85
52-Wochen-HochUS$329.16
52-Wochen-TiefUS$257.17
Beta0.26
1 Monat Veränderung-7.64%
3 Monate Veränderung-5.10%
1 Jahr Veränderung1.72%
3 Jahre Veränderung56.34%
5 Jahre Veränderung33.26%
Veränderung seit IPO3,243.24%

Aktuelle Nachrichten und Updates

Analyse-Update Apr 27

CME: Volatile Street Views And New Futures Will Shape Trading Mix

Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.
Seeking Alpha Apr 23

CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive

Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking Alpha

Recent updates

Analyse-Update Apr 27

CME: Volatile Street Views And New Futures Will Shape Trading Mix

Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.
Seeking Alpha Apr 23

CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive

Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking Alpha
Analyse-Update Apr 11

CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes

The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.
Analyse-Update Mar 26

CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix

Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.
Analyse-Update Mar 11

CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook

Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.
Analyse-Update Feb 25

CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook

The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.
Analyse-Update Feb 10

CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook

The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.
Analyse-Update Jan 27

CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook

The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.
Analyse-Update Jan 12

CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook

Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.
Analyse-Update Dec 27

CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks

Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.
Analyse-Update Dec 13

CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility

Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.
Analyse-Update Nov 16

CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead

The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.
Seeking Alpha Apr 27

CME: More Market Volatility Equals More Demands - Initiating With Strong Buy

Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking Alpha
Seeking Alpha Mar 27

CME Group At A New All-Time High - Valuation Concerns Justified?

Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking Alpha
Seeking Alpha Feb 18

CME Group: High Quality With Good Dividend Yield

Summary CME Group's near-monopoly in futures and options trading, with extraordinary 60% FCF margins, makes it a high-quality, capital-light business despite regulatory costs. Significant acquisitions like CBOT, NYMEX, and KCBT have solidified CME's market dominance, though future focus will be on dividends and smaller acquisitions. CME is slightly undervalued with a 4% dividend yield, making it a strong hold for dividend-focused investors seeking a high-quality business model. Read the full article on Seeking Alpha

Aktionärsrenditen

CMEUS Capital MarketsUS Markt
7D-0.3%0.7%2.1%
1Y1.7%14.0%30.6%

Rendite im Vergleich zur Industrie: CME unter dem Niveau der Branche US Capital Markets , die im vergangenen Jahr eine Rendite von 14% erzielte.

Rendite vs. Markt: CME hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 30.6 erzielte.

Preisvolatilität

Is CME's price volatile compared to industry and market?
CME volatility
CME Average Weekly Movement3.2%
Capital Markets Industry Average Movement3.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stabiler Aktienkurs: CME hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: CMEDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
18983,875Terry Duffywww.cmegroup.com

Die CME Group Inc. betreibt zusammen mit ihren Tochtergesellschaften weltweit Kontraktmärkte für den Handel mit Futures und Optionen auf Futures-Kontrakte. Das Unternehmen bietet Futures und Optionen auf Zinssätze, Aktienindizes und Devisen, Agrar-, Energie- und Metallrohstoffe sowie Dienstleistungen für den Handel mit festverzinslichen Wertpapieren und Devisen an. Das Unternehmen erbringt Clearinghaus-Dienstleistungen, einschließlich Clearing, Abrechnung und Garantie von Futures- und Optionskontrakten, sowie geclearte Swap-Produkte, die über seine Börsen gehandelt werden.

CME Group Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von CME Group im Vergleich zum Marktanteil des Unternehmens?
CME grundlegende Statistiken
MarktanteilUS$104.48b
Gewinn(TTM)US$4.24b
Umsatz(TTM)US$6.74b
24.5x
Kurs-Gewinn-Verhältnis
15.4x
Kurs-Umsatz-Verhältnis

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CME Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$6.74b
Kosten der EinnahmenUS$0
BruttogewinnUS$6.74b
Sonstige AusgabenUS$2.50b
GewinnUS$4.24b

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)11.71
Bruttomarge100.00%
Nettogewinnspanne62.95%
Schulden/Eigenkapital-Verhältnis12.9%

Wie hat sich CME auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

4.0%
Aktuelle Dividendenrendite
43%
Ausschüttungsquote

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/07 11:51
Aktienkurs zum Tagesende2026/05/07 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

CME Group Inc. wird von 34 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Stephen BiggarArgus Research Company
Benjamin BudishBarclays
Roger FreemanBarclays